Uncategorized

Who’s Writing the Scripts and From Where?

rcosentino6da7456864 • October 20, 2026

The person handing a patient a prescription today is less likely to be a physician in a white coat down the hall, and more likely to be a nurse practitioner, a physician associate, or a clinician on a video call. For pharma marketers, that shift matters more than ever. With the FDA moving to tighten broadcast drug advertising, brands need to know exactly who decides what gets prescribed, where that decision happens, and what put the patient in the room in the first place.

Who is writing the scripts

Physicians still write most prescriptions, but more than a quarter now come from someone else. A Komodo Health analysis found non-physicians wrote about 27% of all prescriptions by late 2023, up from 17% in 2016. Nurse practitioners drove most of that gain, rising from 10% to 19% of all scripts, while PAs moved from 6% to 8%.

The growth is uneven by therapy area. Non-physicians now write about a third of prescriptions for common psychiatric drugs, including antidepressants, anti-anxiety and ADHD medications, up from 16% in 2016. They also write 37% of contraceptive prescriptions and 31% of common family medicine drugs. In some specialties, Pharmaceutical Executive reports their share reaches as high as 50%.

The pipeline points one way. Federal workforce projections cited by the AAMC expect NP supply to grow 66% and PA supply 37% between 2024 and 2034, far outpacing physicians. More states also now grant NPs full practice authority, removing the requirement for physician oversight.

Where the scripts come from: the office, the screen, or the app

The physical office still writes the majority of prescriptions, especially first diagnoses and anything requiring an exam. But telehealth has settled into a durable role rather than fading after the pandemic. FAIR Health’s Q1 2026 tracker, summarized by Axis Intelligence, found 18.4% of commercially insured patients filed at least one telehealth claim, with mental health the top diagnosis in every age group and region.

Virtual prescribing is now part of the system’s plumbing. HHS reports that more than 7 million controlled-substance prescriptions were issued via telemedicine in 2024 without a prior in-person visit. The DEA has extended those flexibilities through December 31, 2026, while permanent rules are finalized.

A third channel sits largely outside insurance data: cash-pay direct-to-consumer telehealth platforms for weight loss, hormones, hair and sexual health. These are often intake-questionnaire models. One analysis of nearly 50 GLP-1 telehealth sellers found fewer than a third required a live video or audio consult. Some prescribing decisions now happen in minutes, inside a platform rather than a practice.

How patients get to the prescriber

Most patient journeys now start in a search bar, not a waiting room. A survey for Pacific Lutheran University found one in three Americans always search their symptoms online before seeking care, and 56% have been convinced of a diagnosis from search alone. Most of those searching land on articles that dive deeper into topics like diabetes, psoriasis, asthma, cancer and others. By the time they book, many arrive with a condition name and sometimes an OTC or Rx brand name already in mind.

From there, patients take one of three roads. The traditional path runs through a primary care visit, often with an NP or PA, then a referral to a specialist. A second path runs through urgent care, retail clinics, or a health system’s virtual visit. The third skips the office entirely: a patient sees a social post or ad, clicks into a DTC telehealth platform, fills out an intake form, and receives a prescription by mail.

Insurance shapes which road they take. Covered, chronic conditions still flow through in-network offices. Cash-pay categories with high consumer demand flow to apps.

What drives patient interest

Symptoms bring patients in; advertising, AI, search and social media shape what they ask for once they arrive. A systematic review of DTC research found that few patients book a visit solely because of an ad. More often, they raise an advertised drug or condition during an appointment they already planned. In one FDA survey cited there, 32% of patients asked about a drug because of advertising, and roughly half of those who requested a specific brand received it. Here’s an example of native ads embedded inside the content.

The same review notes 76% of physicians, NPs and PAs said patients had started conversations about brand-name drugs. That makes the prescriber’s response, not just the patient’s request, the deciding moment.

GLP-1 weight-loss drugs show the full loop at work: heavy media coverage and social chatter create demand, search turns it into a condition and a brand, and telehealth platforms convert it into a prescription. Behavioral health follows a similar pattern, which is why it dominates both telehealth claims and NP prescribing growth.

What it means for pharma marketers

The prescriber universe is wider, more mobile and harder to reach than a physician-only target list assumes. NPs and PAs now write more than a quarter of scripts and a third or more in mental health and women’s health, yet they are often missed by conventional targeting.

As the FDA’s proposed rule threatens broadcast DTC, the weight shifts toward reaching every clinician who writes the script, wherever they practice, at the moment a patient walks in with a question. Brands that treat MDs, NPs and PAs as one prescriber audience, across in-office and virtual settings, will be better positioned than those still buying reach on TV alone.

As always, advertising, and marketing more broadly, comes down to repetition. As the saying goes, the first time a prescriber notices you is really the 11th time you’ve reached them. Omnichannel means everywhere, and great marketers engineer the experience rather than leave it to chance.

That experience might start with an ad on the open web, followed by a retargeted ad, an email, an SMS, and an ad in a walled garden like LinkedIn or Facebook. The message then repeats across medical journals, news sites and other digital hubs, until it is clear and impossible to ignore.

Ready to reach your audience?

Become a Tap Native Advertiser or Publisher.

Connect with healthcare professionals at scale. Our platform delivers precision-targeted native advertising to HCPs across the most trusted medical publications.

Tap Native ad units are integrated within the content of popular health, medical and lifestyle sites.

Contact Us

Please fill out the information below and a representative will respond to you as quickly as possible.

Please enter your Name! Please enter your Email Address Please enter your Phone Number! Please Select Services! Please enter your Message!
Please verify your are Human!